World's Best Scientists 2026 revealed!
Yoshio Koyanagi

Yoshio Koyanagi

D-Index & Metrics

Immunology

D-Index
73
Citations
21271
World Ranking
2122
National Ranking
81

Yoshio Koyanagi publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Yoshio Koyanagi sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 275 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Yoshio Koyanagi D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Yoshio Koyanagi sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Yoshio Koyanagi is affiliated with Kyoto University in Japan and has a focused research portfolio primarily within immunology, microbiology, and medicine. Their work spans several interconnected subfields including immunology, infectious diseases, virology, molecular biology, and epidemiology.

The scientist's research has concentrated on several main topics, notably:

  • HIV Research and Treatment
  • Immune Cell Function and Interaction
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS Research and Interventions
  • Interferon and Immune Responses
  • Animal Virus Infections Studies
  • Respiratory Viral Infections Research

Yoshio Koyanagi has contributed to numerous scientific papers with significant publication activity in journals such as:

  • Reviews in Medical Virology
  • Cell Reports
  • bioRxiv (Cold Spring Harbor Laboratory)
  • PLoS Pathogens
  • Journal of Virology

Frequent collaborators include Kei Sato, Jumpei Ito, Hirofumi Aso, Yoriyuki Konno, and Izumi Kimura, reflecting ongoing research partnerships with multiple experts in the field.

Among recent scholarly articles, key publications are:

  • "SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant" (2020, Cell Reports)
  • "SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant" (2020, bioRxiv (Cold Spring Harbor Laboratory))
  • "Endogenous retroviruses drive KRAB zinc-finger protein family expression for tumor suppression" (2020, Science Advances)
  • "Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19" (2021, Cell Reports)
  • "M-Sec facilitates intercellular transmission of HIV-1 through multiple mechanisms" (2020, Retrovirology)

Koyanagi has also contributed to book publications, including the work titled "ARDS in COVID-19 - Insights for Treatment," published in 2023 by Frontiers Media.

Best Publications

  • NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

    Mamoru Ito;Hidefumi Hiramatsu;Kimio Kobayashi;Kazutomo Suzue

  • Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay

    Shinji Harada;Yoshio Koyanagi;Naoki Yamamoto

  • Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

    Yoshio Koyanagi;Steven Miles;Ronald T. Mitsuyasu;Jean E. Merrill

  • HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.

    W. A. O'brien;Y. Koyanagi;Ali Namazie;Jia-Qi Zhao

  • Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

    Hirotaka Ebina;Naoko Misawa;Yuka Kanemura;Yoshio Koyanagi

  • Cytokines alter production of HIV-1 from primary mononuclear phagocytes

    Yoshio Koyanagi;William A. O'Brien;William A. O'Brien;Jia Qi Zhao;David W. Golde

  • A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection

    Tsutomu Murakami;Toshihiro Nakajima;Yoshio Koyanagi;Kazunobu Tachibana

  • Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line

    Naoki Yamamoto;Morihisa Okada;Yoshio Koyanagi;Mari Kannagi

  • High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients

    Shen Pang;Yoshio Koyanagi;Steven Miles;Clayton Wiley

  • Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor.

    J. E. Merrill;Y. Koyanagi;I. S. Y. Chen

  • SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

    Yoriyuki Konno;Izumi Kimura;Keiya Uriu;Masaya Fukushi

  • Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

    R Kikukawa;Y Koyanagi;S Harada;N Kobayashi

  • Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro

    Kenji Maeda;Hirotomo Nakata;Yasuhiro Koh;Toshikazu Miyakawa

  • In vivo infection of human T-cell leukemia virus type I in non-T cells.

    Yoshio Koyanagi;Yasuto Itoyama;Naomi Nakamura;Keita Takamatsu

  • Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.

    S. Horiuchi;Y. Koyanagi;Yongwei Zhou;H. Miyamoto

  • Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1.

    J. E. Merrill;Y. Koyanagi;J. Zack;L. Thomas

  • Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.

    H Nakashima;M Masuda;T Murakami;Y Koyanagi

  • Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection.

    Yasuhiko Munakata;Takako Saito-Ito;Keiko Kumura-Ishii;Jie Huang

  • Host Factor SAMHD1 Restricts DNA Viruses in Non- Dividing Myeloid Cells

    Joseph A. Hollenbaugh;Peter Gee;Jonathon Baker;Michele B. Daly;Michele B. Daly

  • A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.

    Kozi Ichiyama;Sei Yokoyama-Kumakura;Yuetsu Tanaka;Reiko Tanaka

Frequent Co-Authors

Naoki Yamamoto
Naoki Yamamoto Kyoto University
Naoki Yamamoto
Naoki Yamamoto National University of Singapore
Jun-ichi Kira
Jun-ichi Kira Kyushu University
Yorio Hinuma
Yorio Hinuma Kyoto University
Kazuyuki Aihara
Kazuyuki Aihara University of Tokyo
Mamoru Ito
Mamoru Ito Central Institute for Experimental Animals
Yuetsu Tanaka
Yuetsu Tanaka University of the Ryukyus
Akifumi Takaori-Kondo
Akifumi Takaori-Kondo Kyoto University
Irvin S. Y. Chen
Irvin S. Y. Chen University of California, Los Angeles
Tatsutoshi Nakahata
Tatsutoshi Nakahata Kyoto University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare and research careers, often requiring additional specialized education. For those with nursing backgrounds, transitioning to advanced roles involving immunological care is common. Programs like the fnp to acute care np bridge program provide a streamlined path for Family Nurse Practitioners aiming to specialize in acute care settings.

Accelerated pathways are popular for students seeking fast-tracked options. The nurse practitioner accelerated program offers a focused curriculum online, allowing candidates to quickly gain advanced skills necessary for clinical immunology applications.

For those new to nursing or healthcare, foundational degrees are essential. The best online bsn programs for non nurses provide accessible entry points, blending traditional nursing competencies with emerging biomedical knowledge.

Choosing the right program can be challenging, but resources highlighting the easiest absn programs to get into help prospective students find approachable clinical nursing programs that align with their career goals in immunology and beyond.

Best Scientists Citing Yoshio Koyanagi

Trending Scientists

Recently Published Articles